Put companies on watchlist
PolyPeptide Group
ISIN: CH1110760852
WKN: A3CNHV
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

PolyPeptide Group · ISIN: CH1110760852 · EQS - adhoc news (39 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1253109
01 December 2021 07:00AM

PolyPeptide Group appoints Neil Thompson as Director Global Sales and Marketing and member of the Executive Committee, succeeding Jan Christensen


EQS Group-Ad-hoc: PolyPeptide Group / Key word(s): Personnel
PolyPeptide Group appoints Neil Thompson as Director Global Sales and Marketing and member of the Executive Committee, succeeding Jan Christensen

01-Dec-2021 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


Media Release - ad hoc announcement pursuant to Art. 53 LR

PolyPeptide Group appoints Neil Thompson as Director Global Sales and Marketing and member of the Executive Committee, succeeding Jan Christensen

Zug, December 1, 2021 - PolyPeptide Group AG, a global leader in peptide development and manufacturing, today announced the appointment of Neil Thompson as Director Global Sales and Marketing and member of the Executive Committee. As per 1 January 2022, he will succeed Jan Christensen, who will step down after 11 years in the role.

PolyPeptide CEO Raymond De Vré comments: "The two worked together over many years in customer facing roles. This internal succession ensures continuity and reflects well on our internal talent pool. I am excited that Neil accepted the new challenge, and I am grateful to Jan for his inspiring and exemplary leadership. Together with the sales and operations teams, Jan was instrumental in developing today's leading position of PolyPeptide. I am convinced that with Neil's unique mix of technical and sales experience, we are in an excellent position to capture the growth opportunities ahead of us."

Neil James Thompson (49, British) joined PolyPeptide in 2004 and held various sales and business development roles, most recently, since 2019, as Group Commercial Director. He graduated from Liverpool John Moores University with a Bachelor of Science degree in Applied Chemistry and Biochemistry.

Jan Christensen (61, Danish) joined PolyPeptide in 2002 as Head of Generics Europe, then had various positions with increasing responsibilities. In 2010 he was appointed Director Global Sales and Marketing. After stepping down from his executive position in January 2022, Mr. Christensen will support selected business development projects before retiring towards the end of 2022.

Contact
Michael Stäheli, Head of Investor Relations & Corporate Communications
michael.staeheli@polypeptide.com, +41 41 723 20 34

About PolyPeptide
PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products. Dating back to 1952, PolyPeptide today manufactures around one-half of all currently approved peptide drug substances with a global footprint of six GMP-certified facilities in Europe, the U.S. and India. As a multinational company with more than 1'000 employees, its diversity brings breadth, depth of knowledge and experience to the group. PolyPeptide has grown organically and by selective acquisition of existing expertise, culminating in its position today as a leader in outsourced peptide manufacturing. PolyPeptide's shares (SIX: PPGN) are listed on the Swiss Stock Exchange. For more information, visit polypeptide.com.

 

Disclaimer
This release contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.



End of ad hoc announcement
Language: English
Company: PolyPeptide Group
Dammstrasse 19
CH-6300 Zug
Switzerland
Phone: +41 41 723 23 23
E-mail: mediateam@polypeptide.com
Internet: www.polypeptide.com
ISIN: CH1110760852
Valor: 111076085
Listed: SIX Swiss Exchange
EQS News ID: 1253109

 
End of Announcement EQS Group News Service

1253109  01-Dec-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1253109&application_name=news&site_id=boersengefluester_html
Visual performance / price development - PolyPeptide Group
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.